12:00 AM
 | 
Jul 03, 2006
 |  BioCentury  |  Finance

2Q approvals

2Q approvals

2Q approvals
Selected second quarter product approvals. List does not include approvable letters for Nuvigil armodafinil to treat excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome and shift work sleep disorder from Cephalon (CEPH); Fentora fentanyl buccal tablet to manage breakthrough cancer pain from CEPH; and MoviPrep as a bowel-cleansing agent prior to colonoscopy from Salix (SLXP). While not full approvals, the letters did not ask for major data.
Company Approval
Alkermes (ALKS)/ Cephalon (CEPH) FDA approves Vivitrol injectable extended-release naltrexone to treat alcohol dependence
Bioenvision (BIVN)/ Genzyme (GENZ) EC approves Evoltra clofarabine to treat acute lymphoblastic leukemia (ALL) in...

Read the full 547 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >